Cytosorbents (NASDAQ:CTSO) reported Q2 EPS of ($0.25), $0.12 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $9.58 million.
Cytosorbents (NASDAQ:CTSO) reported Q2 EPS of ($0.25), $0.12 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $9.58 million.